Scientists hunt for clues in Parkinson's blood after Year-Long drug trial
NCT ID NCT05677633
Summary
This study tested the safety of a 48-week treatment with a drug called Leukine (sargramostim) in 11 people with Parkinson's disease. Researchers closely monitored participants for side effects and collected blood samples to look for biological changes, or 'biomarkers,' that might show how the drug affects the immune system and symptoms. The main goal was to gather safety information and identify potential signs that could help design future, larger studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE AND PARKINSONISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Nebraska Medical Center
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.